Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma
暂无分享,去创建一个
P. Sterk | H. Hoogsteden | Z. Diamant | S. Rohatagi | J. Prins | S. Millet | B. Miller | J. Kuperus | R. Baan | K. Nietzmann | P. Mendes | D. Amin | P. Sterk | H. C. Hoogsteden | Jan-Bas Prins | P. J. Sterk | Henk C. Hoogsteden | Shashank Rohatagi
[1] B. Jensen,et al. Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler , 2004, American journal of therapeutics.
[2] B. Jensen,et al. Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA‐4 Antagonist, HMR1031 , 2003, Journal of clinical pharmacology.
[3] M. Robinson,et al. The effect of anti-integrin monoclonal antibodies on antigen-induced pulmonary inflammation in allergic rabbits. , 2003, Pulmonary pharmacology & therapeutics.
[4] P. O'Byrne,et al. Allergen‐induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation , 2003, Immunology.
[5] W. Hagmann,et al. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. , 2003, American journal of respiratory and critical care medicine.
[6] I. Pavord,et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.
[7] A. Zwinderman,et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids. , 2002, American journal of respiratory and critical care medicine.
[8] P. Sterk,et al. Standardised methodology of sputum induction and processing , 2002, European Respiratory Journal.
[9] David Y Jackson,et al. Alpha 4 integrin antagonists. , 2002, Current pharmaceutical design.
[10] H. Popper,et al. Expression of adhesion molecules in allergic lung diseases , 2002, Virchows Archiv.
[11] K. Konstantopoulos,et al. CCR3-Active Chemokines Promote Rapid Detachment of Eosinophils from VCAM-1 In Vitro1 , 2000, The Journal of Immunology.
[12] R. Djukanović,et al. The relationship between airways inflammation and asthma severity. , 2000, American journal of respiratory and critical care medicine.
[13] J. Vandenbroucke,et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. , 1999, American journal of respiratory and critical care medicine.
[14] D. Staunton,et al. αdβ2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1) , 1998, The Journal of experimental medicine.
[15] K C Lin,et al. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. , 1998, Current opinion in chemical biology.
[16] M. Elices,et al. Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. , 1997, American journal of respiratory and critical care medicine.
[17] P. Barnes,et al. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. , 1997, The European respiratory journal.
[18] S. Kharitonov,et al. Exhaled and nasal nitric oxide measurements : recommendations , 1997 .
[19] P. Sterk,et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. , 1996, The European respiratory journal.
[20] M. Jordana,et al. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. , 1996, American journal of respiratory and critical care medicine.
[21] E. Knol,et al. Mechanisms regulating eosinophil extravasation in asthma. , 1996, The European respiratory journal. Supplement.
[22] P. O'Byrne,et al. Reproducibility of allergen-induced early and late asthmatic responses. , 1995, The Journal of allergy and clinical immunology.
[23] P. Sterk,et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. , 1995, The Journal of allergy and clinical immunology.
[24] S. Anderson,et al. Airway responsiveness : standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993 .
[25] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[26] Z. Tomori,et al. Comparison of inspiratory effort in sniff-like aspiration reflex, gasping and normal breathing in cats. , 1993, The European respiratory journal.
[27] R. Djukanović,et al. Mucosal inflammation in asthma. , 1990, The American review of respiratory disease.
[28] D. Cockcroft,et al. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.